Apimeds Pharmaceuticals US, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
MindWave Innovations, a subsidiary of Apimeds Pharmaceuticals US ($7.8M market cap), entered two 12-month technology services agreements: (1) with Singapore-based AQUAE Holdings to deploy MindChain infrastructure powering AQUAEChain, with MindWave receiving 20% allocation of ALCI Credits issued quarterly, plus software/service fees (effective Sept 14, 2026); (2) with Flash Sports Media Holdings (ticker FLZH) to build and operate FlashChain for ticketing/media, with MindWave receiving FLZH common shares and 20% allocation of FLASH TOKEN, plus 50% annual maintenance fee (effective Sept 29, 2026). Specific dollar amounts undisclosed; both agreements reference potential 5-year and annual renewal paths respectively.
Why this rating
Two revenue contracts for MindWave subsidiary with token allocations; dollar amounts unknown relative to $7.8M parent; moderate scale with execution risk and unproven token/ALCI market valuations.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.